An international study published by the New England Journal of Medicine, in which participate Vall d'Hebron Research Institute (VHIR) and the Center of Multiple sclerosis of Catalonia (CEM-Cat) determines that the oral drug Laquinimod reduces the progression of disability and the quantity of relapses in multiple sclerosis.
Dr. Xavier Montalban, chief of the Clinical neuroimmunology group at VHIR and director of CEM-Cat, has taken part in the international study in phase III about the efficiency of the oral drug Laquinimod, which has been carried out in 139 centers of 24 different countries. The study has counted with the participation of 1.106 patients with multiple sclerosis that received a Laquinimod's oral daily dose of 0.6mg or placebo for 24 months. The primary aim was to analyze the number of relapses during this period. The secondary aims of the study were to analyze the progression of disability and injuries.
VHIR in the media: Diario Médico, Vilaweb, Europa Press